Functional Genetics, Inc. Receives Award to Discover New Opportunities to Combat HIV Infection
Functional Genetics, Inc. Announces a New Award from the National Institute of Allergy and Infectious Diseases to Utilize Its Core Random Homozygous Gene Perturbation and Host-Oriented Therapeutics Technologies to Identify and Validate New Therapeutic Approaches to Combat HIV Infection
Gaithersburg, MD, June 03, 2007 --(PR.com)-- Functional Genetics, Inc. announced today that it has received an award from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to discover new opportunities to treat HIV, the cause of AIDS.
"This new award allows Functional Genetics to apply its innovative new approaches to help in the fight against HIV/AIDS," said Michael Goldblatt, Chief Executive Officer. “Functional Genetics is dedicated to discovering new drugs that protect and treat virus infections that cause considerable death and disease. The Company has already applied its approaches to develop broad-spectrum therapeutics designed to prevent or treat diseases that impact both the civilian and military communities.”
Functional Genetics will apply its proprietary Random Homozygous Gene Perturbation (RHGP) technology to identify host targets for drugs that can be safely delivered to prevent or treat HIV infection. “This new opportunity complements Functional Genetics’ pioneering efforts to develop broad-spectrum anti-infectives based on the concept of denying microbes the opportunity to harm patients,” added Dr. Goldblatt. The program is designed to overcome issues that have previously eluded anti-infective therapies, including acquired drug resistance and the narrow application of current antivirals.
About Functional Genetics, Inc.
Functional Genetics is a privately-held biopharmaceutical company dedicated to advancing science to combat intractable human diseases. The company's initial therapeutic products, through its innovative focus of Host Oriented Therapeutics, address the unmet medical need for effective therapies to combat a broad spectrum of infectious diseases. These new drugs are designed to circumvent microbial resistance, which often causes therapeutic failures. Functional Genetics has identified and is establishing medical validity of therapeutics that target host proteins required for the propagation and pathogenicity of disease-causing viruses including HIV, Influenza, RSV, and diseases of bioterrorism such as Ebola. The Company is currently moving toward clinical testing of the first of its new generation of broad spectrum anti-viral products. The Company's has also developed technologies that dramatically increase the efficiency of biomedicine production. Functional Genetics is headquartered in Gaithersburg, Maryland. For more information, visit the company's website at http://www.functional-genetics.com.
Source: Functional Genetics, Inc.
Contact: Media: Michael Kinch at 240-631-6799.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Functional Genetics’ business which are not historical facts are "forward-looking statements" that involve risks and uncertainties.
###
"This new award allows Functional Genetics to apply its innovative new approaches to help in the fight against HIV/AIDS," said Michael Goldblatt, Chief Executive Officer. “Functional Genetics is dedicated to discovering new drugs that protect and treat virus infections that cause considerable death and disease. The Company has already applied its approaches to develop broad-spectrum therapeutics designed to prevent or treat diseases that impact both the civilian and military communities.”
Functional Genetics will apply its proprietary Random Homozygous Gene Perturbation (RHGP) technology to identify host targets for drugs that can be safely delivered to prevent or treat HIV infection. “This new opportunity complements Functional Genetics’ pioneering efforts to develop broad-spectrum anti-infectives based on the concept of denying microbes the opportunity to harm patients,” added Dr. Goldblatt. The program is designed to overcome issues that have previously eluded anti-infective therapies, including acquired drug resistance and the narrow application of current antivirals.
About Functional Genetics, Inc.
Functional Genetics is a privately-held biopharmaceutical company dedicated to advancing science to combat intractable human diseases. The company's initial therapeutic products, through its innovative focus of Host Oriented Therapeutics, address the unmet medical need for effective therapies to combat a broad spectrum of infectious diseases. These new drugs are designed to circumvent microbial resistance, which often causes therapeutic failures. Functional Genetics has identified and is establishing medical validity of therapeutics that target host proteins required for the propagation and pathogenicity of disease-causing viruses including HIV, Influenza, RSV, and diseases of bioterrorism such as Ebola. The Company is currently moving toward clinical testing of the first of its new generation of broad spectrum anti-viral products. The Company's has also developed technologies that dramatically increase the efficiency of biomedicine production. Functional Genetics is headquartered in Gaithersburg, Maryland. For more information, visit the company's website at http://www.functional-genetics.com.
Source: Functional Genetics, Inc.
Contact: Media: Michael Kinch at 240-631-6799.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Functional Genetics’ business which are not historical facts are "forward-looking statements" that involve risks and uncertainties.
###
Contact
Functional Genetics, Inc.
Michael Kinch
240-631-6790
www.functional-genetics.com
Michael Kinch
240-631-6790
www.functional-genetics.com
Contact
Categories